Canaccord downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, down from $73, after the company entered into an agreement to be acquired by Novo Nordisk (NVO) for $54 per share in cash and a non-transferable contingent value right for up to $6 per share upon full U.S. regulatory approval of efruxifermin.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics rises 16.5%
- Video: Delta soars after earnings, lifts airline peers
- Morning Movers: Akero jumps after deal to be bought by Novo Nordisk
- M&A News: Akero Therapeutics Stock (AKRO) Zooms 19% after Novo Nordisk Buys it for $5.2B
- Akero Therapeutics jumps 18% to $54.74 after Novo Nordisk buyout offer